# Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

> **NCT03604419** · PHASE2 · COMPLETED · sponsor: **PegBio Co., Ltd.** · enrollment: 214 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** PB-119 100 μg+ Glucophage®
- **DRUG:** PB-119 150 μg+ Glucophage®
- **DRUG:** PB-119 200 μg+ Glucophage®
- **DRUG:** PB-119 placebo + Glucophage®

## Key facts

- **NCT ID:** NCT03604419
- **Lead sponsor:** PegBio Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-13
- **Primary completion:** 2019-07-23
- **Final completion:** 2019-07-23
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2020-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03604419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03604419, "Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03604419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*